Norfloxacin: More than 20 years of its clinical use, the results and place among fluoroquinolones in modern chemotherapy in infections

Antibiotiki i Khimioterapiya

Volumn 48, Issue 9, 2003, Pages 28-36

  Padeiskaya, E N ^a  

^a Alliance of Clinical Chemotherapists and Microbiologists   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; NORFLOXACIN;

CHEMICAL STRUCTURE; CHEMISTRY; COMMUNICABLE DISEASE; COMPARATIVE STUDY; DRUG EFFECT; ENTEROBACTERIACEAE; GASTROENTERITIS; HUMAN; KIDNEY; METABOLISM; MICROBIOLOGY; REVIEW; SEXUALLY TRANSMITTED DISEASE; UROGENITAL TRACT DISEASE;

ANTI-INFECTIVE AGENTS; COMMUNICABLE DISEASES; ENTEROBACTERIACEAE; FEMALE UROGENITAL DISEASES; GASTROENTERITIS; HUMANS; KIDNEY; MALE UROGENITAL DISEASES; MOLECULAR STRUCTURE; NORFLOXACIN; SEXUALLY TRANSMITTED DISEASES, BACTERIAL;

EID: 1842840110     PISSN: 02352990     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Ito A., Hirai K., Inoue M. et al. In vitro activity of AM-715, anew nalidixic acid analog. Antimicrob Agents Chemother 1980; 17: 103-108.
2. Holmes B., Brogden R. N., Richards D. M. Norfloxacin. A review of its antibacterial activity, phamacokinetic properties and therapeutic use. Drugs 1985; 30: 482-513.
3. Russian source
4. Russian source
5. Gadebursch H. Y., Shugu D. L. Norfloxacin, the first of new class of fluoroquinolone antimicrobials, revisited. Intern J Antimicrob Agents 1991; 3-28.
6. Phillips I., King A., Shannon K. In vitro properties of the quinolones. The Quinolones./2nd ed. Andriole V. T. ed., Academic Press, 1998; 81-116.
7. Wilson A. P. R., Gruneberg R. N. Ciprofloxacin: 10 years of cunical experience. Maxim Medical. Oxford, 1997; 273.
8. Russian source
9. Eandi M., Viano I., DiNola F. et al. Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hapatic damage. Eur J Clin Micriobiol 1983; 2: 3: 253-259.
10. Bergan T. Pharmacokinetics of the fluoroquinolones. The Quinolones/ 2nd ed., Andriole V. T. ed. Academic Press, 1998; 143-182.
11. Russian source
12. Swanson B., Boppana V. K., Vlasses P. N. Norfloxacin disposition after sequencial oral doses. Antimicrob Agents Chemother 1983; 33: 284-288.
13. Russian source
14. Russian source
15. Norrby S. R. Treatment of urinary tract infections with quinolone antimicrobial agents. Quinolone Antimicrobial Agents. /2nd ed. Hooper D. C., Wolfson J. S, eds. Washington, 1993; 273-283.
16. Naber K. G. Role of quinolones in treatment of chronic bacteral prostatitis. Ibid., 285-297.
17. Nicolle L. E. Use of quinolones in urinary tract infection and prostatitis. The Quinolones /2nd ed. Andriole V. T. ed. Academic Press, 1998; 183-202.
18. DiCarlo R. P., Martin D. H. Use of the quinolones in sexually transmitted diseases. Ibid., 203-228.
19. Russian source
20. Russian source
21. Hamer D. H., Gorbach S. I. Use of the quinolones for the treatment and prophylaxis of bacterial gastrointestinal infections. The Quinolones. /2nd ed. Andriole V. T. ed. Academic Press, 1998; 267-286.
22. Hooper D. S., Wolfson J. S. Adverse effects of the quinolones. Quinolone Antimicrobial Agents. /2nd ed., Hooper D. S., Wolfson J. S. eds. Washington, 1993; 482-512.
23. Russian source
24. Russian source
25. Russian source
26. Aujard Y., Gendrel D. Les quinolone en pediatrie. Paris, 1994; 124.
27. Russian source
28. Russian source
29. Russian source
30. Russian source